awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q41386664-0CB80ABB-F920-4C46-B8BC-1359F6B51C59
Q41386664-0CB80ABB-F920-4C46-B8BC-1359F6B51C59
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41386664-0CB80ABB-F920-4C46-B8BC-1359F6B51C59
Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.
P2860
Q41386664-0CB80ABB-F920-4C46-B8BC-1359F6B51C59
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41386664-0CB80ABB-F920-4C46-B8BC-1359F6B51C59
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
220e39875189e3bb9da07df3ee58a64cbbcefb4a
P2860
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.